肿瘤坏死因子家族及其相关药物的研究进展

被引：20

作者：

冯速 ^{[1
,2
]}

邱樊 ^{[1
]}

张壮壮 ^{[1
]}

华子春 ^{[1
,2
,3
]}

机构：

[1] 南京大学生命科学学院医药生物技术国家重点实验室

[2] 南京大学常州高新技术研究院暨江苏省产业技术研究院医药生物技术研究所

[3] 南京大学深圳研究院

来源：

药学进展 | 2016年 / 40卷 / 04期

关键词：

肿瘤坏死因子家族; 细胞凋亡; 药物靶点; 生物药物;

D O I：

暂无

中图分类号：

R91 [药物基础科学];

学科分类号：

100705 [微生物与生化药学];

摘要：

细胞凋亡是进化保守的重要生物学过程,具有重要的生理和病理作用,如在免疫系统的发育与稳态以及多种疾病(包括肿瘤)的发生、发展、预后及治疗等过程中起重要作用。因此,近年来参与细胞凋亡信号转导的肿瘤坏死因子(TNF)/TNF受体(TNFR)家族的重要成员TNFα/TNFR、Fas/Fas L和TRAIL/TRAILR成为重要的药物靶点,并开发出多个相关靶向药物,尤其是生物药物,其中有些在临床疗效和商业上获得巨大成功。简介参与细胞凋亡信号转导的TNF/TNFR家族重要成员,着重对其通过介导细胞凋亡而发挥的生物学作用及其相关药物研发作一综述,希望对我国的药物研发有所裨益。

引用

页码：284 / 292

页数：9

共 11 条

[1]

TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies.[J].Peter A. Holoch;Thomas S. Griffith.European Journal of Pharmacology.2009, 1

[2]

COMBINATION OF THE PRO-APOPTOTIC TRAIL-RECEPTOR ANTIBODY MAPATUMUMAB WITH IONIZING RADIATION STRONGLY INCREASES LONG-TERM TUMOR CONTROL UNDER AMBIENT AND HYPOXIC CONDITIONS [J].

Marini, Patrizia ;

Budach, Wilfried ;

Niyazi, Maximilian ;

Junginger, Dorothea ;

Stickl, Stefan ;

Jendrossek, Verena ;

Belka, Claus .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01) :198-202

[3]

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.[J].Finnberg; Niklas;Klein-Szanto; Andres J P;El-Deiry; Wafik S.Journal of Clinical Investigation.2008, 1

[4]

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein [J].

Stieglmaier, Julia ;

Bremer, Edwin ;

Kellner, Christian ;

Liebig, Tanja M. ;

ten Cate, Bram ;

Peipp, Matthias ;

Schulze-Koops, Hendrik ;

Pfeiffer, Matthias ;

Buehring, Hans-Joerg ;

Greil, Johann ;

Oduncu, Fuat ;

Emmerich, Bertold ;

Fey, Georg H. ;

Helfrich, Wijnand .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (02) :233-246

[5]

The promise of TRAIL - potential and risks of a novel anticancer therapy [J].

Koschny, Ronald ;

Walczak, Henning ;

Ganten, Tom M. .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2007, 85 (09) :923-935

[6]

Isolated limb perfusion with melphalan and tumor necrosis factor α for advanced melanoma and soft-tissue sarcoma [J].

Hayes, Andrew J. ;

Neuhaus, Susan J. ;

Clark, Matthew A. ;

Thomas, J. Meirion .

ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) :230-238

[7]

Tumor necrosis factor-α receptor p75 is required in ischemia-induced neovascularization [J].

Goukassian, David A. ;

Qin, Gangjian ;

Dolan, Christine ;

Murayama, Toshinori ;

Silver, Marcy ;

Curry, Cynthia ;

Eaton, Elizabeth ;

Luedemann, Corinne ;

Ma, Hong ;

Asahara, Takayuki ;

Zak, Victor ;

Mehta, Shanu ;

Burg, Aaron ;

Thorne, Tina ;

Kishore, Raj ;

Losordo, Douglas W. .

CIRCULATION, 2007, 115 (06) :752-762

[8]

Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO [J].

Ea, CK ;

Deng, L ;

Xia, ZP ;

Pineda, G ;

Chen, ZJJ .

MOLECULAR CELL, 2006, 22 (02) :245-257

[9]

GENETIC DISORDERS OF PROGRAMMED CELL DEATH IN THE IMMUNE SYSTEM <sup>*</sup>.[J].Nicolas Bidère;Helen C. Su;Michael J. Lenardo.Annual Review of Immunology.2006, 1

[10]

Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis infections [J].

Olleros, ML ;

Guler, R ;

Vesin, D ;

Parapanov, R ;

Marchal, G ;

Martinez-Soria, E ;

Corazza, N ;

Pache, JC ;

Mueller, C ;

Garcia, I .

AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (04) :1109-1120

← 1 2 →